Hefei Medical Engineering Pharmaceutical

Hefei medical and Pharmaceutical Co., Ltd. is a private pharmaceutical company founded in Anhui Province, China in 1994, focused on the development, manufacturing, and commercialization of small molecule drugs for immune system, nervous system, infectious, skin/musculoskeletal, and cardiovascular diseases. The company’s pipeline includes both generic chemical drugs and novel small molecules targeting well-characterized proteins such as histamine H1 receptor and thromboxane A2 synthase. The clinical pipeline spans from IND through phase III to approved products; notable examples include desloratadine citrate disodium for allergic rhinitis (approved), ibuprofen for acute fever (phase III), HY‑072808 for atopic dermatitis via PDE4 inhibition (phase III), pyragrel sodium for acute ischemic stroke via TXA2 synthase inhibition. The company appears active with no indication it has been acquired or merged into another entity[1].